Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
Go back to Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis| Johnson & Johnson (NYSE: JNJ) | Delayed: 267.91 -1.21 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $269.12 | 52 Week High | $126.07 | |||
| Open | $268.51 | 52 Week Low | $94.28 | |||
| Day High | $270.10 | P/E | 55.70 | |||
| Day Low | $266.73 | EPS | $4.81 | |||
| Volume | 2,172,397 | |||||
